Nanomix Corporation announced an agreement with Mobility Health, whereby Nanomix and Mobility Health plan to collaborate in the development of an LDT (Lab Developed Test) that can be deployed in a fully mobile lab to evaluate levels of circulating antibodies to COVID-19. Nanomix plans to supply the product elements and Mobility Health plans to complete development and validation of the test, with plans to file for a CLIA Lab Emergency Use Authorization (EUA) with the FDA.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -.--% | -.--% | -.--% |
2023 | Nanomix Corporation Announces Chief Executive Officer Changes | CI |
2023 | Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 4.9K | |
+42.32% | 9.46B | |
+33.70% | 4.36B | |
-40.24% | 2.21B | |
-9.44% | 1.63B | |
-28.89% | 1.2B | |
-43.71% | 974M | |
-10.86% | 936M | |
-47.63% | 739M | |
-31.84% | 581M |
- Stock Market
- Equities
- NNMX Stock
- News Nanomix Corporation
- Nanomix Corporation Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies